Infinata’s BioPharm Insight to Host New Educational Webinar, “Investing in Sunshine: How to Leverage Cloud Computing to Help Meet the New Requirements”

Share Article

Sunshine Act expected to spur cloud provider growth and M&A interest.

BioPharm Insight™ will host a new webinar, “Investing in Sunshine: How to Leverage Cloud Computing to Help Meet the New Requirements,” on Wednesday, August 28, 2013 at 10:00 a.m. EDT. BioPharm Insight, part of Infinata, a Financial Times Group company, is a leading provider of business intelligence solutions which also includes BioPharm Clinical™, High Net Worth Insight™ and wealthmonitor™. To register for the webinar, please click here.

The Physician Payments Sunshine Act came into force this month, which requires providers to disclose compensation received from medical industry companies. Pharma, biotech and medical device companies are now required to submit these reports to the Centers for Medicare & Medicaid Services (CMS) on an annual basis. The majority of this information will also be available publicly.

Failure to comply could lead to charges of up to USD 100,000 per incidence.

In a BioPharm Insight article entitled: ‘Sunshine Act open payment requirements to spur cloud-provider growth and M&A interest,’ experts noted that accurately collecting consistent information could be difficult in today’s clinical trial environment as a result of the number of outsourced providers and partners involved in clinical trials. The new legislation could spur growth for cloud providers which enable all parties – including sponsors, contract research organisations (CROs) and partners – to conveniently upload and access data from anywhere in the world via a virtual network.

In a recent follow-up article, experts told BioPharm Insight the common concerns about sending sensitive clinical and company information into the cloud network and ways providers can allay these fears.

On the webinar, Sunshine Act specialists Tina Fan, director of Acquis Consulting, Tim Immel, Chief Product Officer and Founder of Clinverse and Attorney Sarah Crotts from law firm Womble Carlyle will join BioPharm Insight’s Natalie Morrison to discuss:

  •     The Sunshine Act requirements
  •     Common issues arising from the newly implemented laws
  •     Ways to leverage cloud technology to simplify the new workload
  •     M&A and partnerships between technology providers to meet standards
  •     Perceptions and realities in terms of cloud-based security

To register for the webinar, please click here.

About the Presenters
Tina Fan, Director, Acquis Consulting – Ms. Fan majored in engineering and previously worked for Accenture. As well as consulting on the Sunshine Act, she has authored a number of white pipers and articles surrounding the new legislation.

Sarah Crotts, Attorney, Womble Carlyle – Ms. Crotts works in healthcare regulatory compliance and specializes in Medicare and Medicaid reimbursement, as well as Health Insurance Portability and Accountability Act (HIPAA) and the implementation and use of health information technology.

Tim Immel, Chief Product Officer and Founder, Clinverse – Mr. Immel is the co-founder of Clinverse which delivers cloud-based financial management and payment solutions for the healthcare sector. He has over 20 years of experience in financial management and operations, and specialises in software development and innovation for business processes.

Natalie Morrison, Reporter, BioPharm Insight – Ms. Morrison covers a wide range of pharma and biotech news specializing in the pharmaceutical industry contract services sector. She was behind the publication’s recent series of articles on the cloud sector.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit

Media Contact:
Holly Burke

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Holly Burke
+1 (781) 619-0131
Email >
since: 12/2008
Follow >
Biopharm Insight

Visit website